Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.53
-0.0300-0.54%
Volume:845.72K
Turnover:4.61M
Market Cap:814.01M
PE:-9.44
High:5.53
Open:5.48
Low:5.39
Close:5.56
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.64
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:6.53
PE(LYR):-10.43

Loading ...

Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Jul 30, 2025

Major Issues Report

Form 8-K - Current report
Jun 30, 2025

Major Issues Report

Form 8-K - Current report
Jun 05, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 05, 2025

Major Issues Report

Form 8-K - Current report
May 09, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2025

Major Issues Report

Form 8-K - Current report
Mar 05, 2025

Correspondence

Form CORRESP - Correspondence
Feb 27, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2025

Major Issues Report

Form 8-K - Current report
Jan 13, 2025

Major Issues Report

Form 8-K - Current report
Dec 27, 2024

Correspondence

Form CORRESP - Correspondence
Nov 27, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 25, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 22, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 21, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 18, 2024

Major Issues Report

Form 8-K - Current report
Nov 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]